Search results
J&J’s Tremfya superior to Stelara in Phase II/III Chron’s disease trials
Clinical Trials Arena via Yahoo Finance· 3 weeks agoJohnson and Johnson’s Johnson and Johnson’s Tremfya (guselkumab) was superior to its Stelara...
AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals
Zacks via Yahoo Finance· 9 months agoAbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week...
AbbVie joins in latest gastrointestinal drug chase
BioPharma Dive via Yahoo Finance· 10 hours agoAbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate...
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
Benzinga via Yahoo Finance· 1 year agoThe FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active...
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
Zacks via Yahoo Finance· 2 months agoBristol Myers BMY announced that a late-stage study on orally-administered Zeposia (ozanimod) in...
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Zacks via Yahoo Finance· 3 weeks agoShares of Eli Lilly LLY rose nearly 3% on Tuesday after it reported detailed one-year results from...
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Reuters via Yahoo Finance· 1 year agoJohnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster...
What Could This Drug News Mean for AbbVie?
Motley Fool· 2 years agoIn late July, AbbVie (NYSE: ABBV) applied for a new indication with the European Medicines Agency (EMA) for Rinvoq to treat adult patients with...
Johnson & Johnson Clocks 12% Q4 Revenue Growth, Led By Cancer and Crohn's Disease Drugs
Benzinga via Yahoo Finance· 5 months agoOn Tuesday, Johnson & Johnson (NYSE:JNJ) reported fourth-quarter 2023 adjusted earnings of $2.29 per...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 3 weeks agoEli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising...
